[Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
The efficacy of UDCA (10 mg/kg/day) in combination with SAMe (heptral, 800-1600 mg/day) vs UDCA alone was evaluated in the treatment of 19 patients (age 36-57) with primary biliary cirrhosis. It was found that the combination UDCA + SAMe promoted earlier and steadier disease remission. Normalization of biochemical parameters of cholestase (serum bilirubin, cholesterol, total bile acids, alkaline phosphatase, 5-nucleotidase and jamma-glutamyl transpeptidase) was recorded in 33%, and a significant reduction--in the rest patients. Heptral potentiates cytoprotective and anticholestatic actions of UDCA, but has a weak action on its immunomodulatory and antiapoptotic effects.
Avezov
S A
SA
Mansurova
F Kh
FKh
D000328:Adult; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy*; D008875:Middle Aged; D012436:S-Adenosylmethionine / Q000627:therapeutic use*; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid; D012436:S-Adenosylmethionine